

## **Product** Data Sheet

# β-Amyloid peptide(16-20)

 Cat. No.:
 HY-P5124

 CAS No.:
 153247-40-6

 Molecular Formula:
  $C_{35}H_{52}N_6O_6$ 

Molecular Weight: 652.82

**Sequence:** Lys-Leu-Val-Phe-Phe

Sequence Shortening: KLVFF

Target: Amyloid-β

Pathway: Neuronal Signaling

**Storage:** Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years -20°C 1 year

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light, under nitrogen)

#### **SOLVENT & SOLUBILITY**

In Vitro

H<sub>2</sub>O: 33.33 mg/mL (51.06 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.5318 mL	7.6591 mL	15.3182 mL
	5 mM	0.3064 mL	1.5318 mL	3.0636 mL
	10 mM	0.1532 mL	0.7659 mL	1.5318 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

Description β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of Amyloid-β (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH<sub>2</sub> residues added at N- and C-terminal ends to aid solubility)<sup>[1]</sup>.

In Vitro β-Amyloid peptide(16-20) (-NH2) inhibits Abeta fibril formation under a dose of 1:2 molar ratio (Aβ40/peptide), after incubation for 12 days (37  $\boxtimes$ )<sup>[1]</sup>.

incubation for 12 days (37 M).

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$ 

#### REFERENCES

[1]. Austen BM, et al. Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide. Biochemistry. 2008 Feb 19;47(7):1984-92.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com